Characterization by liquid chromatography combined with mass spectrometry of monoclonal anti-IGF-1 receptor antibodies produced in CHO and NS0 cells.

7H2HM is a new humanized recombinant monoclonal antibody (MAb) directed against insulin-like growth factor-1 receptor and produced in CHO cells. Homogeneity of intact antibody, reduced light and heavy chains, Fab and Fc fragments were investigated by analytical methods based on mass (SDS-PAGE, SEC), charge (IEF, C-IEX) and hydrophobicity differences (RP-HPLC, HIC) and compared side-by-side with A2CHM, produced in NS0 cells. Primary structures and disulfide bridge pairing were analyzed by microsequencing (Edman degradation), mass spectrometry (MALDI-TOF, ES-TOF) and peptide mapping after enzymatic digestion (Trypsin, endoprotease Lys-C, papain). The light chains demonstrated the expected sequences. The heavy chains yielded post-translational modifications previously reported for other recombinant humanized or human IgG1 such as N-terminal pyroglutamic acid, C-terminal lysine clipping and N-glycosylation for asparagine 297. More surprisingly, two-thirds of the 7H2HM heavy chains were shown to contain an additional 24-amino-acid sequence, corresponding to the translation of an intron located between the variable and the constant domains. Taken together these data suggest that 7H2HM is a mixture of three families of antibodies corresponding (i) to the expected structure (17%; 14,9297 Da; 1330 amino acids), (ii) a variant with a translated intron in one heavy chains (33%; 15,2878 Da; 1354 amino acids) and (iii) a variant with translated introns in two heavy chains (50%; 15,4459 Da; 1378 amino acids), respectively. RP-HPLC is not a commonly used chromatographic method to assess purity of monoclonal antibodies but unlike to SEC and SDS-PAGE, was able to show and to quantify the family of structures present in 7H2HM, which were also identified by peptide mapping, mass spectrometry and microsequencing.

[1]  E. Julien,et al.  Residual DNA quantification in clinical batches of BBG2Na, a recombinant subunit vaccine against human respiratory syncytial virus. , 2001, Biologicals : journal of the International Association of Biological Standardization.

[2]  J. L. Bailey,et al.  Techniques in protein chemistry , 1989 .

[3]  T. Raju,et al.  Species-specific variation in glycosylation of IgG: evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics. , 2000, Glycobiology.

[4]  James E. Bailey,et al.  Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity , 1999, Nature Biotechnology.

[5]  K. Shitara,et al.  The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity* , 2003, The Journal of Biological Chemistry.

[6]  M. Trikha,et al.  Monoclonal antibodies as therapeutics in oncology. , 2002, Current opinion in biotechnology.

[7]  S. Tsunasawa,et al.  Pyrrolidone carboxyl peptidase from the hyperthermophilic Archaeon Pyrococcus furiosus: cloning and overexpression in Escherichia coli of the gene, and its application to protein sequence analysis. , 1998, Journal of biochemistry.

[8]  M. Mulkerrin,et al.  Validation of an HPLC method for the analysis of the charge heterogeneity of the recombinant monoclonal antibody IDEC-C2B8 after papain digestion. , 1997, Journal of pharmaceutical and biomedical analysis.

[9]  G. Hale,et al.  Manufacture and quality control of CAMPATH-1 antibodies for clinical trials. , 2001, Cytotherapy.

[10]  L. Presta,et al.  Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human FcγRIII and Antibody-dependent Cellular Toxicity* , 2002, The Journal of Biological Chemistry.

[11]  J. Brass,et al.  Quality assurance after process changes of the production of a therapeutic antibody. , 1996, Pharmaceutica acta Helvetiae.

[12]  L. Presta Antibody engineering for therapeutics. , 2003, Current opinion in structural biology.

[13]  M. Butler,et al.  Comparisons of the Glycosylation of a Monoclonal Antibody Produced under Nominally Identical Cell Culture Conditions in Two Different Bioreactors , 2000, Biotechnology progress.

[14]  E. Drewe,et al.  Clinically useful monoclonal antibodies in treatment. , 2002, Journal of clinical pathology.

[15]  R. Mhatre,et al.  Strategies for locating disulfide bonds in a monoclonal antibody via mass spectrometry. , 1999, Rapid communications in mass spectrometry : RCM.

[16]  L. Presta,et al.  Isomerization of an aspartic acid residue in the complementarity-determining regions of a recombinant antibody to human IgE: identification and effect on binding affinity. , 1996, Biochemistry.

[17]  V. Shankar,et al.  Therapeutic applications of monoclonal antibodies , 2011 .

[18]  R. Dwek,et al.  Glycosylation changes of IgG associated with rheumatooid arthritis can activate complement via the mannose-binding protein , 1995, Nature Medicine.

[19]  S. Carr,et al.  An integrated strategy for structural characterization of the protein and carbohydrate components of monoclonal antibodies: application to anti-respiratory syncytial virus MAb. , 1995, Analytical chemistry.

[20]  Nigel Jenkins,et al.  Getting the glycosylation right: Implications for the biotechnology industry , 1996, Nature Biotechnology.

[21]  A. Chen,et al.  Validation of a capillary isoelectric focusing method for the recombinant monoclonal antibody C2B8. , 1998, Journal of chromatography. A.

[22]  G. Wang,et al.  Variant antibody identification by peptide mapping. , 1999, Biotechnology and bioengineering.

[23]  R. Huber,et al.  Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. , 2003, Journal of molecular biology.

[24]  J L Cleland,et al.  Antioxidants for prevention of methionine oxidation in recombinant monoclonal antibody HER2. , 1997, Journal of pharmaceutical sciences.

[25]  A. Alexander,et al.  Monitoring of IgG antibody thermal stability by micellar electrokinetic capillary chromatography and matrix-assisted laser desorption/ionization mass spectrometry. , 1995, Analytical chemistry.

[26]  J. Bonnefoy,et al.  Stability and CTL-activity of P40/ELA melanoma vaccine candidate. , 2001, Biologicals : journal of the International Association of Biological Standardization.

[27]  D K Robinson,et al.  Industrial choices for protein production by large-scale cell culture. , 2001, Current opinion in biotechnology.

[28]  P. Carter,et al.  Improving the efficacy of antibody-based cancer therapies , 2001, Nature Reviews Cancer.

[29]  P. Roepstorff,et al.  Characterization of a recombinant monoclonal antibody by mass spectrometry combined with liquid chromatography. , 2001, Journal of chromatography. B, Biomedical sciences and applications.

[30]  E. Julien,et al.  Stability and CTL activity of N-terminal glutamic acid containing peptides. , 2001, Journal of Peptide Research.

[31]  S. Langermann,et al.  Increasing the Affinity of a Human IgG1 for the Neonatal Fc Receptor: Biological Consequences1 , 2002, The Journal of Immunology.

[32]  J. Gebler,et al.  Letter: The Use of Electrospray Ionization Mass Spectrometry to Distinguish the Lot-to-Lot Heterogeneity of An Antigen Specific Monoclonal Antibody from a Specific Cellular Clone , 1999 .

[33]  A. Jonsson Mass spectrometry for protein and peptide characterisation , 2001, Cellular and Molecular Life Sciences CMLS.

[34]  Inger Sandlie,et al.  Therapeutic antibodies for human diseases at the dawn of the twenty-first century , 2003, Nature Reviews Drug Discovery.

[35]  P. T. Jones,et al.  Replacing the complementarity-determining regions in a human antibody with those from a mouse , 1986, Nature.

[36]  M. Jefford,et al.  Rational approaches to human cancer immunotherapy , 2003, Journal of leukocyte biology.

[37]  A. Chen,et al.  Capillary isoelectric focusing and sodium dodecyl sulfate-capillary gel electrophoresis of recombinant humanized monoclonal antibody HER2. , 1996, Journal of chromatography. A.

[38]  C. Beddell,et al.  Mass spectrometry of the humanized monoclonal antibody CAMPATH 1H. , 1995, Analytical chemistry.

[39]  Wei Zhang,et al.  Complete disulfide bond assignment of a recombinant immunoglobulin G4 monoclonal antibody. , 2002, Analytical biochemistry.

[40]  S. Chamow,et al.  Therapeutic antibody expression technology. , 2001, Current opinion in biotechnology.

[41]  J L Cleland,et al.  A specific molar ratio of stabilizer to protein is required for storage stability of a lyophilized monoclonal antibody. , 2001, Journal of pharmaceutical sciences.

[42]  A. Dickson,et al.  Characterization of the stability of recombinant protein production in the GS-NS0 expression system. , 2001, Biotechnology and bioengineering.

[43]  B. Kabakoff,et al.  Identification of multiple sources of charge heterogeneity in a recombinant antibody. , 2001, Journal of chromatography. B, Biomedical sciences and applications.

[44]  P. Pauwels,et al.  A recombinant humanized anti‐insulin‐like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti‐epidermal growth factor receptor therapy against human cancer xenografts , 2005, International journal of cancer.

[45]  J. Rohrer,et al.  Protein variant separations using cation exchange chromatography on grafted, polymeric stationary phases , 2001, Proteomics.

[46]  C. Mantzoros,et al.  The Role of the IGF System in Cancer: From Basic to Clinical Studies and Clinical Applications , 2002, Oncology.

[47]  Michael Butler,et al.  A study of immunoglobulin G glycosylation in monoclonal and polyclonal species by electrospray and matrix-assisted laser desorption/ionization mass spectrometry. , 2002, Analytical biochemistry.

[48]  F. Emmrich,et al.  Purification and analytical characterization of an anti-CD4 monoclonal antibody for human therapy. , 1994, Journal of chromatography. A.

[49]  L. Taylor,et al.  Characterization of monoclonal antibody glycosylation: comparison of expression systems and identification of terminal alpha-linked galactose. , 1997, Analytical biochemistry.

[50]  T. Nguyen,et al.  Synthesis and characterization of Respiratory Syncytial Virus protein G related peptides containing two disulfide bridges. , 2000, The journal of peptide research : official journal of the American Peptide Society.

[51]  M Vanderlaan,et al.  Industrial Purification of Pharmaceutical Antibodies: Development, Operation, and Validation of Chromatography Processes , 2001, Biotechnology & genetic engineering reviews.

[52]  I. Krull,et al.  Characterization of recombinant human monoclonal tissue necrosis factor-alpha antibody using cation-exchange HPLC and capillary isoelectric focusing. , 1999, Analytical biochemistry.

[53]  T. Nguyen,et al.  Development of a quantitative assay for residual host cell proteins in a recombinant subunit vaccine against human respiratory syncytial virus. , 2001, Journal of immunological methods.

[54]  T. Torphy,et al.  Monoclonal antibodies: boundless potential, daunting challenges , 2002 .

[55]  Janice M Reichert,et al.  Therapeutic monoclonal antibodies: trends in development and approval in the US. , 2002, Current opinion in molecular therapeutics.